- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03753269
Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction
Efficacy of Early Intracoronary Administration of Fasudil Hydrochloride on Myocardial Perfusion in the Primary PCI of ST-elevation Myocardial Infarction: an Prospective, Randomized and Multicenter Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Timely reperfusion therapy is the most effective treatment for acute STEMI patients. Primary PCI has been documented as the best method for restoration of epicardial blood flow. Nevertheless, recovery of epicardial blood flow does not necessarily equate to a sufficient reperfusion at myocardial level. Although epicardial TIMI 3 flow could be achieved in the majority of STEMI patients by contemporary PPCI, it has been well acknowledged that microvascular obstruction (MVO) is far more prevalent than the epicardial no-reflow phenomenon and has huge detrimental impact on clinical outcomes.
Routine thrombus aspiration by special catheter during primary PCI has shown negative or even harmful results in clinical trials. Distal coronary protective devices are also ineffective to improve myocardial perfusion. On the contrary, peri-procedual administration of several medications has shown possibilities to reduce MVO. These medications are mostly anti-platelet agents such as GP IIb/IIIa receptor and microvascular dilators like adenosine, sodium nitroprusside and verapamil. Theoretically, intracoronary delivery of medications can be more effective and potentially decrease side effects. Empirical application of aforementioned agents seems to improve the epicardial flow in patients not achieving TIMI 3 flow after PCI. However, it is debatable whether early administration of intracoronary medication (meaning before PCI) may further reduce MVO assuming it could be better to reduce reperfusion injury. However, this has not been well investigated yet.
Rho-associated protein kinase (Rho kinase) is expressed in many cells, including smooth muscle cells and vascular endothelial. Activation of Rho kinase leads to increased smooth muscle intracellular calcium and robust vasoconstriction. Fasudil hydrochloride is a rho-kinase inhibitor that severs clinically as a potent small vessel dilator, especially in the field of cerebral circulation. Meanwhile, It has been empirically used in individual STEMI cases and showed effectiveness in improving coronary flow for PCI therapy. This study aims to evaluate whether an early intracoronary administration of Fasudil Hydrochloride can improve myocardial perfusion and clinical outcomes for STEMI patients undergoing primary PCI. To ensure the complete delivery of agents within coronary, a special-designed targeted perfusion micro-catheter will be used for drug delivery. Patients in the control arm will be administrated by intracoronary saline.
For the results, coronary angiography-based index of epical and myocardial perfusion will be analyzed. MVO will be determined by cardiac magnetic resonance imaging and quantified as the percentage of left ventricular myocardial mass (% LV). The rate of composite major adverse cardiac events (MACEs) at 30 days and 6 months since symptom onset will be the clinical outcomes.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jun Pu, Professor
- Phone Number: +86-21-68383164
- Email: pujun310@hotmail.com
Study Contact Backup
- Name: Heng Ge, M.D
- Email: dr.geheng@foxmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age: over 18 or 18 years old, less than 75 years old;
- Patents with myocardial infarction who have symptom onset within 6h before randomization;
- ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ;
- Signed informed consent form prior to trial participation
Exclusion Criteria:
- ECG with new left bundle branch block;
- Contraindications for CMR
- Repeated STEMI
History of cardiovascular diseases
- PCI within previous 1 month or Previous coronary-artery bypass surgery (CABG)
- Previously known multi-vessel coronary artery disease not suitable for revascularization
- Hospitalization for cardiac reason within past 48 hours
- Known acute pericarditis and/or subacute bacterial endocarditis
- Arterial aneurysm, arterial/venous malformation and aorta dissection;
History of other severe diseases
- Any other diseases with life expectancy ≤12 months
- • Any history of severe renal or hepatic dysfunction (hepatic failure, cirrhosis, portal hypertension and active hepatitis); Neutropenia, thrombocytopenia; Known acute pancreatitis
Severe cardiac complications
- Any sign of cardiac rupture
- Cardiogenic shock (SBP <90 mmHg after fluid infusion or SBP<100 mmHg after vasoactive drugs)
Not suitable for clinical trial
- Inclusion in another clinical trial;
- Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days;
- Pregnancy or lactating;
- Body weight <40kg or >125kg;
- Known allergy to any drug that may appear in the study
- Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fasudil Hydrochloride
Fasudil Hydrochoride will be delivered into culprit vessel right after the first wire passage
|
2.5mg fasudil hydrochloride (diulted to 15ml by 0.9% saline )will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
|
Placebo Comparator: Placebo saline
Same volume of 0.9% saline will be delivered into culprit vessel right after the first wire passage
|
15ml 0.9% saline will be delivered by targeted perfusion micro-catheter into culprit vessel right after the first wire passage
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete epicardial and myocardial reperfusion after PCI
Time Frame: PCI procedure
|
The percentage of patient achieving both thrombolysis in myocardial infarction (TIMI) flow grade (TFG) 3 for epicardial reperfusion and TIMI myocardial perfusion (TMPG) grade 3 for myocardial reperfusion
|
PCI procedure
|
CMR-derived microvascular obstruction (MVO)
Time Frame: Within one week after the STEMI onset
|
MVO is defined as hypoenhanced area within infracted zone presented by CMR gadolinium late enhancement imaging.
MVO will be quantified as the percentage of LV mass (% LV)
|
Within one week after the STEMI onset
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CMR-derived infarction size
Time Frame: Within one week of STEMI onset, repeated on the sixth month
|
Infarct size was determined by the extent of late gadolinium enhancement on CMR and expressed as a percentage of LV mass (% LV)
|
Within one week of STEMI onset, repeated on the sixth month
|
TIMI Flow Grade (TFG)
Time Frame: PCI procedure
|
Percentage of patients achieving TFG 3
|
PCI procedure
|
TIMI Myocardial Perfusion Grade (TMPG)
Time Frame: PCI procedure
|
Percentage of patients achieving TMPG 3
|
PCI procedure
|
TMPFC
Time Frame: PCI procedure
|
Mean or median value of TMPFC
|
PCI procedure
|
Complete ST-segment Resolution
Time Frame: 90 minutes after PCI procedure
|
Percentage of patients achieving ≥ 70% resolution of the initial sum of ST-segment elevation
|
90 minutes after PCI procedure
|
MACEs
Time Frame: 30 days and 6 months after STEMI onset
|
Incidence of major adverse cardiac events (MACEs) as a composite of all cause death, nonfatal reinfarction, heart failure and stroke after PCI
|
30 days and 6 months after STEMI onset
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med. 1985 Apr 4;312(14):932-6. doi: 10.1056/NEJM198504043121437. No abstract available.
- Ding S, Pu J, Qiao ZQ, Shan P, Song W, Du Y, Shen JY, Jin SX, Sun Y, Shen L, Lim YL, He B. TIMI myocardial perfusion frame count: a new method to assess myocardial perfusion and its predictive value for short-term prognosis. Catheter Cardiovasc Interv. 2010 Apr 1;75(5):722-32. doi: 10.1002/ccd.22298.
- Gibson CM, Cannon CP, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe CH, Van De Werf F, Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation. 2000 Jan 18;101(2):125-30. doi: 10.1161/01.cir.101.2.125.
- Kidambi A, Mather AN, Motwani M, Swoboda P, Uddin A, Greenwood JP, Plein S. The effect of microvascular obstruction and intramyocardial hemorrhage on contractile recovery in reperfused myocardial infarction: insights from cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2013 Jun 27;15(1):58. doi: 10.1186/1532-429X-15-58.
- Taniguchi Y, Funayama H, Matsuda J, Fujita K, Nakagawa T, Nakamura T, Umemoto T, Mitsuhashi T, Ako J, Momomura S. Super-selective intracoronary injection of Rho-kinase inhibitor relieves refractory coronary vasospasms: a case report. Int J Cardiol. 2014 Sep;176(1):270-1. doi: 10.1016/j.ijcard.2014.06.096. Epub 2014 Jul 8. No abstract available.
- Masumoto A, Hirooka Y, Shimokawa H, Hironaga K, Setoguchi S, Takeshita A. Possible involvement of Rho-kinase in the pathogenesis of hypertension in humans. Hypertension. 2001 Dec 1;38(6):1307-10. doi: 10.1161/hy1201.096541.
- Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997 Oct 30;389(6654):990-4. doi: 10.1038/40187.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Myocardial Infarction
- Infarction
- ST Elevation Myocardial Infarction
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Membrane Transport Modulators
- Protein Kinase Inhibitors
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Fasudil
Other Study ID Numbers
- EARLY-MYO-FASUDIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ST Segment Elevation Myocardial Infarction
-
Inha University HospitalCompletedST Segment Elevation Myocardial Infarction | Non-ST Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
RenJi HospitalCompletedST Segment Elevation Myocardial Infarction
-
Dong-A UniversityTerminatedST-Segment Elevation Myocardial InfarctionKorea, Republic of
-
Azienda Ospedaliera San Camillo ForlaniniUnknownST Segment Elevation Myocardial InfarctionItaly
-
Jinan Central HospitalUnknownST-Segment Elevation Myocardial InfarctionChina
-
Assiut UniversityNot yet recruitingST-segment Elevation Myocardial Infarction (STEMI)
-
Assiut UniversityUnknownST-segment Elevation Myocardial Infarction (STEMI)
-
Hellenic Cardiovascular Research SocietyCompletedMyocardial Infarction | ST Segment Elevation Myocardial Infarction (STEMI)Greece
-
Lisata Therapeutics, Inc.CompletedST Segment Elevation Myocardial InfarctionUnited States
Clinical Trials on Fasudil Hydrochloride
-
Technical University of MunichRecruitingIdiopathic Parkinson´s DiseaseGermany
-
Brigham and Women's HospitalDoris Duke Charitable FoundationTerminated
-
Colorado State UniversityCompleted
-
Woolsey PharmaceuticalsCompleted
-
Woolsey PharmaceuticalsActive, not recruitingAmyotrophic Lateral SclerosisUnited States, Australia
-
Brigham and Women's HospitalCompletedAtherosclerosis | HypercholesterolemiaUnited States
-
Shahid Beheshti University of Medical SciencesUnknownRetinopathy of PrematurityIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesUnknownRetinal Vein OcclusionIran, Islamic Republic of
-
Shahid Beheshti University of Medical SciencesCompletedDiabetic Macular EdemaIran, Islamic Republic of
-
Woolsey PharmaceuticalsActive, not recruitingProgressive Supranuclear Palsy | Corticobasal SyndromeUnited States